The DNA damage response activates HPV16 late gene expression at the level of RNA processing

Kersti Nilsson, Chengjun Wu, Naoko Kajitani, Haoran Yu, Efthymios Tsimtsirakis, Lijing Gong, Ellenor B. Winquist, Jacob Glahder, Lars Ekblad, Johan Wennerberg, Stefan Schwartz

Research output: Contribution to journalArticlepeer-review


We show that the alkylating cancer drug melphalan activated the DNA damage response and induced human papillomavirus type 16 (HPV16) late gene expression in an ATM- and Chk1/2-dependent manner. Activation of HPV16 late gene expression included inhibition of the HPV16 early polyadenylation signal that resulted in read-through into the late region of HPV16. This was followed by activation of the exclusively late, HPV16 splice sites SD3632 and SA5639 and production of spliced late L1 mRNAs. Altered HPV16 mRNA processing was paralleled by increased association of phosphorylated BRCA1, BARD1, BCLAF1 and TRAP150 with HPV16 DNA, and increased association of RNA processing factors U2AF65 and hnRNP C with HPV16 mRNAs. These RNA processing factors inhibited HPV16 early polyadenylation and enhanced HPV16 late mRNA splicing, thereby activating HPV16 late gene expression.

Original languageEnglish
Pages (from-to)5029-5049
JournalNucleic Acids Research
Issue number10
Publication statusPublished - 2018 Jan 1

Subject classification (UKÄ)

  • Medical Genetics


Dive into the research topics of 'The DNA damage response activates HPV16 late gene expression at the level of RNA processing'. Together they form a unique fingerprint.

Cite this